静脉注射胺碘酮与普罗帕酮治疗阵发性室上性心动过速疗效的Meta分析  

A meta-analysis of amiodarone and propafenone treatment of supraventricular tachycardia

作　　者：王少波[1] 梁锦军[1] 黄从新[1] 

机构地区：[1]武汉大学人民医院心内科,430060

出　　处：《疑难病杂志》2013年第1期2-4,共3页Chinese Journal of Difficult and Complicated Cases

摘　　要：目的系统评价静脉注射胺碘酮与普罗帕酮治疗阵发性室上性心动过速的疗效与安全性。方法计算机检索1999—2012年中英文电子文献数据库,收集有关胺碘酮和普罗帕酮治疗阵发性室上性心动过速的随机对照试验(RCT),应用Cochrane协作网提供的RevMan 5.1软件进行系统评价。结果最终纳入5篇文献,(1)静脉注射胺碘酮组与普罗帕酮组治疗阵发性室上性心动过速疗效:两药差异无统计学意义(OR=1.45,95%CI 0.83～2.51,P>0.05);漏斗图分析结果未发现显著偏倚。(2)静脉注射胺碘酮组与普罗帕酮组治疗阵发性室上性心动过速不良反应:胺碘酮组不良反应发生率低于普罗帕酮组(OR=0.47,95%CI 0.29～0.77,P<0.01);漏斗图分析结果未发现显著偏倚。结论 (1)胺碘酮与普罗帕酮治疗阵发性室上性心动过速疗效无明显差异。(2)胺碘酮的不良反应发生率低于普罗帕酮。Objective To evaluate the efficacy and safety of intravenous amiodarone and propafenone in treating paroxysmal supraventricular tachycardia with the meta analysis.Methods Randomized controlled trials（RCT）included written in Chinese and English concerned using amiodarone and propafenone in treatment of paroxysmal supraventricular tachycardia were collected from 1999 to 2012 in a meta-analysis.The RevMan 5.1 software of Cochrane Coordination Net was used for statistical analysis.Results The therapy of amiodarone group and propafenone group in the treatment of paroxysmal supraventricular tachycardia effect analysis were;integrated test results was（OR=1.45,95%CI 0.83-2.51,P 0.05）.The funnel plot analysis showed no significant bias.The adverse reaction analysis of amiodarone group and propafenone group therapy in the treatment of paroxysmal supraventricular tachycardia as follows;integrated lest results was（OR=0.47,95%CI 0.29 ~ 0.77,P 0.05）.The funnel plot analysis showed no significant bias.Conclusion The amiodarone group and propafenone group therapy in the treatment of paroxysmal supraventricular tachycardia were showed no obvious differences.The incidence of adverse reactions of the amiodarone were lower than the propafenone.

关 键 词：胺碘酮 普罗帕酮 心动过速 室上性 阵发性 META分析 

分 类 号：R541.7[医药卫生—心血管疾病]